Recently, de novo mutations in ATP1A3 have been shown to cause AHC, rapid-onset dystonia-Parkinsonism (RDP), and cerebellar ataxia, areflexia, pes cavus, optic atrophy and sensorineural hearing loss (CAPOS) syndrome [2–13]. Here, ATP1A3 is linked to Pes cavus.